Xopenex and Symdeko drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xopenex (levalbuterol hydrochloride) and Symdeko (ivacaftor; ivacaftor, tezacaftor). Common drug interactions include infective pulmonary exacerbation of cystic fibrosis among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Xopenex and Symdeko. It is created by eHealthMe based on reports of 95 people who take the same drugs from the FDA, and is updated regularly.

What is Xopenex?

Xopenex has active ingredients of levalbuterol hydrochloride. It is often used in asthma. eHealthMe is studying from 13,816 Xopenex users. Check the latest studies of Xopenex.

What is Symdeko?

Symdeko has active ingredients of ivacaftor; ivacaftor, tezacaftor. eHealthMe is studying from 5,996 Symdeko users. Check the latest studies of Symdeko.

On Jul, 06, 2026

95 people who take Xopenex and Symdeko together, and have interactions are studied.

What are the common drug interactions of Xopenex and Symdeko, by gender? *:

female:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Hospitalisation
Pneumonia
Infection
Vomiting
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Constipation
Cough
Headache (pain in head)
Nausea (feeling of having an urge to vomit)

male:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Infection
Bacterial infection
Depressed mood
Dyspepsia (indigestion)
Fatigue (feeling of tiredness)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Mood altered (changes in mood)

What are the common drug interactions of Xopenex and Symdeko, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Alanine aminotransferase increased
Aspartate aminotransferase increased

10-19:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Pneumonia
Aggression
Depressed mood
Influenza
Nausea (feeling of having an urge to vomit)
Procedural vomiting
Sinusitis bacterial (bacterial infection of sinus)
Viral infection

20-29:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Nausea (feeling of having an urge to vomit)
Vomiting
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Hospitalisation
Infection
Chest pain
Death
Disturbance in attention
Dizziness

30-39:

Oropharyngeal pain
Abdominal pain
Aphonia (inability to produce voice)
Chest pain
Decreased appetite
Dysphonia (speech disorder attributable to a disorder of phonation)
Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Mycotic allergy (fungal allergy)
Nephrolithiasis (calculi in the kidneys)

40-49:

Influenza like illness
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

50-59:

n/a

60+:

Dyspnoea (difficult or laboured respiration)
Respiratory tract congestion (blockage on respiratory system)
Abdominal pain
Abnormal faeces (abnormal stool)
Constipation
Weight increased

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 93 people, 97.89%

* Approximation only. Some reports may have incomplete information.

Do you take Xopenex and Symdeko?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously